INMB (INmune Bio) Margin of Safety % (DCF Earnings Based): N/A (As of Jun. 24, 2026)


INMB INmune Bio Inc INMB
52 GF Score
Price $1.35
GF Value $1.84
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is INmune Bio Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

INmune Bio's Predictability Rank is Not Rated. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

INMB vs GRDX, VERU, ABVC: Margin of Safety % (DCF Earnings Based) Comparison

For the Biotechnology subindustry, INmune Bio's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

INmune Bio Margin of Safety % (DCF Earnings Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, INmune Bio's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where INmune Bio's Margin of Safety % (DCF Earnings Based) falls into.


INMB
52GF Score
INmune Bio Inc INMB
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is INmune Bio (INMB) Overvalued in 2026?

Based on GuruFocus' analysis, INmune Bio stock appears to be undervalued. The current stock price of $1.35 is trading 26.6% below its estimated GF Value™ of $1.84. GuruFocus considers INmune Bio to be Modestly Undervalued.

Key valuation signals for INMB:

  • Margin of Safety % (DCF Earnings Based): N/A
  • GF Value™: $1.84 vs. price of $1.35 (26.6% below fair value)
  • GF Score™: 52/100 with 4 warning signs

No single metric tells the full story. See the INMB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

INmune Bio Business Description

Address 225 NE Mizner Boulevard, Suite 640, Boca Raton, FL, USA, 33432
INmune Bio Inc is a clinical stage biotechnology pharmaceutical company focused on developing and commercializing its product candidates to treat diseases where inflammation and immunology cause a dysfunctional immune system contributing to disease. The company's pipeline products include INKmune, XPro1595, and others. It has three product platforms; The CORDStrom product platform, The DN-TNF product platform, and The Natural Killer Cell Priming Platform.
52GF Score

Get the complete analysis for INMB

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.35
Price
$1.84
GF Value